HIV-1 variant, infectious recombinant virus with specific mutations in the RT gene as indicated. These mutations confer resistance to specific HIV RT inhibitors and have been reported for emerging virus in vivo.
HIV-1 variant, infectious recombinant virus with specific mutations in the RT gene as indicated. These mutations confer resistance to specific HIV RT inhibitors and have been reported for emerging virus in vivo.
HIV-1 variant, infectious recombinant virus with specific mutations in the RT gene as indicated. These mutations confer resistance to specific HIV RT inhibitors and have been reported for emerging virus in vivo.
Plasmid contains the entire genome of HIV-1 with specific mutations in the reverse transcriptase gene, which can confer drug resistance to specific HIV-1 inhibitors. The respective mutations have been reported in viruses from HIV-infected individuals on reverse transcriptase inhibitors with virologic therapy failure.
Plasmid contains the entire genome of HIV-1 with specific mutations in the reverse transcriptase gene, which can confer drug resistance to specific HIV-1 inhibitors. The respective mutations have been reported in viruses from HIV-infected individuals on reverse transcriptase inhibitors with virologic therapy failure.
This recombinant HIV-1 variant contains a common polymorphism, which has been described as increasing viral replication in the presence of fitness-reducing Pr mutations
Infectious cell culture supernatant. This Human Mastadenovirus C, Type 6 (isolate 1546/08) is preserved under Viral Storage Medium -80°C. Tests for the presence of mycoplasmae were positive.
Infectious cell culture supernatant. This Human Mastadenovirus C, Type 5 (isolate 77/12) is preserved under Viral Storage Medium -80C. The virus contains mycoplasma.
Infectious cell culture supernatant. This Human Mastadenovirus C, Type 1 (isolate 2131/08) is preserved under Viral Storage Medium -80C. Tests for the presence of mycoplasmae were negative.
